Clinical trials: Neuroectodermal Tumor
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Retinoblastoma
Photoscreening for Retinoblastoma
Retinoblastoma is the most common pediatric eye malignancy and manifests between 1 and 5 years of age. The tumor is most often diagnosed by leukocoria ( white reflex in the pupil).
- Trial name
- NCT04344652
- Testing
- Photoscreening -
- Volunteers
- healthy volunteers welcome
- Sponsor
- Phoenix Children's Hospital
Metastatic Melanoma
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and…
- Trial name
- NCT00881049
- Testing
- Imatinib (Gleevec)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Melanoma, Kidney Neoplasms
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of…
- Conditions
- Melanoma, Kidney Neoplasms, Metastases
- Trial name
- NCT00095108
- Testing
- Recombinant Human Interleukin-21
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- ZymoGenetics
Melanoma, Unresectable (Stage III) Melanoma
RTA 408 Capsules in Patients With Melanoma - REVEAL
Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths.
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Trial name
- NCT02259231
- Testing
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg)
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Biogen
Oligodendroglioma, Adult
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
RATIONALE: Current therapies for adult recurrent/progressive oligodendrogliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003472
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Burzynski Research Institute
Glioma, Glioma, Malignant
Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
This retrospective study aims to assess the utility of 2D non-navigated intraoperative ultrasound (ioUS) as a cost-effective alternative for guiding the surgical resection of gliomas and for detecting residual tumor.
- Conditions
- Glioma, Glioma, Malignant, Low-grade Glioma, High-grade Glioma
- Trial name
- 2D-ioUS-Glio (NCT05873946)
- Testing
- intraoperative ultrasound
- Where
- Spain
- Volunteers
- 99 people
- Sponsor
- Hospital del Rio Hortega
Melanoma, Urothelial Carcinoma
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
- Trial name
- NCT05823246
- Testing
- QLF31907
- Where
- 6 sites in China
- Volunteers
- 66 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neuroendocrine Tumors
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
The purpose of the protocol is to evaluate the long-term safety of medicine 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072 or 177Lu-OPS201) for patients who have previously received 177Lu-satoreotide tetraxetan in the…
- Trial name
- NCT05017662
- Testing
- Data collection
- Where
- 7 sites in Australia, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Ariceum Therapeutics GmbH
Abdominal Neuroblastoma
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma
High risk neuroblastoma (NB) is an aggressive, prevalent non-brain cancer derived from nerve cells of the body. It mostly affects infants, and more children die from this tumor each year than are cured.
- Trial name
- NCT01440283
- Testing
- Intensity Modulated Radiation Therapy (IMRT)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroendocrine Tumors
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.
- Trial name
- NCT03112694
- Testing
- Data collection
- Where
- 8 sites in United States
- Volunteers
- 93 people
- Sponsor
- Ipsen
Giant Cell Glioblastoma, Glioblastoma
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01957956
- Testing
- Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Malignant Melanoma
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
- Trial name
- NCT03383237
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Melanoma
Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma
The incidence of Melanoma is rapidly growthing,and in China,dacarbazine combined with cisplatin is conmendly used as the first-line chemotherapy of metastatic melanoma.
- Trial name
- NCT03095079
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University Cancer Hospital & Institute
Glioma
A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma
To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide in subjects…
- Trial name
- KARE003 (NCT00660283)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kentuckiana Cancer Institute
Rectal Neoplasms, Neuroendocrine Tumors
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors
we evaluated all related clinical and pathologic data of rectal NET cases, including the resection margin status, NET grading, and lymphovascular invasion status.
- Trial name
- NCT06143605
- Testing
- salvage treatment
- Volunteers
- 527 people
- Sponsor
- Yanhong Deng
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Liver Cancer
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
The goal of this clinical research study is to find the highest tolerable dose of the combination of everolimus with TheraSphere that can be given to patients with advanced NETs that have spread to the liver.
- Trial name
- NCT01864070
- Testing
- TheraSphere, Everolimus, Phone Call
- Sponsor
- M.D. Anderson Cancer Center